KR100443306B1 - 사이클로스포린 또는 마크롤라이드를 포함하는 에멀젼예비농축물 - Google Patents

사이클로스포린 또는 마크롤라이드를 포함하는 에멀젼예비농축물 Download PDF

Info

Publication number
KR100443306B1
KR100443306B1 KR10-2000-7009861A KR20007009861A KR100443306B1 KR 100443306 B1 KR100443306 B1 KR 100443306B1 KR 20007009861 A KR20007009861 A KR 20007009861A KR 100443306 B1 KR100443306 B1 KR 100443306B1
Authority
KR
South Korea
Prior art keywords
composition
component
fatty acid
weight
cyclosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-7009861A
Other languages
English (en)
Korean (ko)
Other versions
KR20010041657A (ko
Inventor
앰부흘미쉘
룩켈바르바라
리흐터프리드리히
하버린바르바라
마인저아민
Original Assignee
노바티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100443306(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9804742.6A external-priority patent/GB9804742D0/en
Priority claimed from GBGB9805104.8A external-priority patent/GB9805104D0/en
Priority claimed from GBGB9805199.8A external-priority patent/GB9805199D0/en
Application filed by 노바티스 아게 filed Critical 노바티스 아게
Publication of KR20010041657A publication Critical patent/KR20010041657A/ko
Application granted granted Critical
Publication of KR100443306B1 publication Critical patent/KR100443306B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR10-2000-7009861A 1998-03-06 1999-03-04 사이클로스포린 또는 마크롤라이드를 포함하는 에멀젼예비농축물 Expired - Fee Related KR100443306B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9804742.6 1998-03-06
GBGB9804742.6A GB9804742D0 (en) 1998-03-06 1998-03-06 Organic compounds
GB9805104.8 1998-03-10
GBGB9805104.8A GB9805104D0 (en) 1998-03-10 1998-03-10 Organic compounds
GB9805199.8 1998-03-11
GBGB9805199.8A GB9805199D0 (en) 1998-03-11 1998-03-11 Organic compounds

Publications (2)

Publication Number Publication Date
KR20010041657A KR20010041657A (ko) 2001-05-25
KR100443306B1 true KR100443306B1 (ko) 2004-08-09

Family

ID=27269231

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7009861A Expired - Fee Related KR100443306B1 (ko) 1998-03-06 1999-03-04 사이클로스포린 또는 마크롤라이드를 포함하는 에멀젼예비농축물

Country Status (29)

Country Link
EP (2) EP1059913B1 (enExample)
JP (2) JP2002505271A (enExample)
KR (1) KR100443306B1 (enExample)
CN (1) CN1195495C (enExample)
AR (1) AR015729A1 (enExample)
AT (1) ATE277599T1 (enExample)
AU (1) AU749217B2 (enExample)
BE (3) BE1012400A5 (enExample)
BR (1) BR9908597A (enExample)
CA (1) CA2322845C (enExample)
CO (1) CO4930289A1 (enExample)
CZ (1) CZ301967B6 (enExample)
DE (2) DE69920668T2 (enExample)
ES (1) ES2228014T3 (enExample)
FR (4) FR2775596B1 (enExample)
GB (1) GB2350791B (enExample)
HU (1) HUP0101080A3 (enExample)
ID (1) ID25908A (enExample)
IL (2) IL138248A0 (enExample)
IT (1) IT1313550B1 (enExample)
MY (1) MY129274A (enExample)
NO (1) NO331800B1 (enExample)
NZ (1) NZ506644A (enExample)
PE (1) PE20000324A1 (enExample)
PT (1) PT1059913E (enExample)
SK (1) SK285139B6 (enExample)
TR (1) TR200002586T2 (enExample)
TW (3) TWI236912B (enExample)
WO (1) WO1999044584A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP1135150B1 (en) * 1998-12-11 2012-10-17 Tris Pharma, Inc. Self-emulsifying compositions for drugs poorly soluble in water
US7026290B1 (en) * 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2127400A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and process for preparation thereof
GB2362573A (en) * 2000-05-25 2001-11-28 Cipla Ltd Cyclosporin formulation
EP1227793A1 (en) * 1999-11-02 2002-08-07 Cipla Ltd. Cyclosporin formulation
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
WO2003002095A1 (fr) * 2001-06-28 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Preparation d'une micro-emulsion de type huile-eau
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
KR20040047056A (ko) * 2002-11-29 2004-06-05 한미약품 주식회사 비페닐디메틸디카복실레이트의 경구용 마이크로에멀젼조성물
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
KR20040084240A (ko) * 2003-03-27 2004-10-06 (주) 코스메디 고형지질나노입자, 이를 함유하는 활성성분 전달용약학조성물 및 이의 제조방법
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2005302501A1 (en) * 2004-10-29 2006-05-11 Novartis Ag Spontaneously dispersible pharmaceutical compositions
WO2006102157A1 (en) * 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
CN101032620B (zh) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 一种环孢素自乳化制剂及其制备方法
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
WO2009117152A1 (en) 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5567909B2 (ja) * 2010-06-17 2014-08-06 東洋カプセル株式会社 タクロリムス含有カプセル剤
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
ES2969933T3 (es) 2012-12-31 2024-05-23 Jrx Biotechnology Inc Formulaciones farmacéuticas tópicas líquidas en nanoemulsión
KR101458466B1 (ko) * 2013-06-24 2014-11-07 한국화학연구원 면역억제제가 봉입된 마이셀을 함유하는 경구제
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
BR112021009967A2 (pt) * 2018-11-26 2021-08-17 Hepion Pharmaceuticals, Inc. formulações farmacêuticas de análogos de ciclosporina
WO2024014958A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Lides formulation platform
WO2024014959A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Micelle-generating formulations with improved hydrophobicity
CN117797093A (zh) * 2024-02-29 2024-04-02 中国农业科学院农业环境与可持续发展研究所 一种以大环内酯类药物为活性成分的兽用口服纳米液体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793966A1 (en) * 1996-03-05 1997-09-10 Hanmi Pharm. Co. Ltd Cyclosporin-containing topical pharmaceutical composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
WO1995022343A1 (en) * 1994-02-17 1995-08-24 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
GB2308546B (en) * 1994-10-26 1999-06-02 Novartis Ag Topical macrolide compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
EP1039893B1 (en) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793966A1 (en) * 1996-03-05 1997-09-10 Hanmi Pharm. Co. Ltd Cyclosporin-containing topical pharmaceutical composition

Also Published As

Publication number Publication date
DE19983012T1 (de) 2001-02-01
CN1195495C (zh) 2005-04-06
TR200002586T2 (tr) 2000-11-21
EP1354582A3 (en) 2004-06-09
HK1034038A1 (en) 2001-10-12
IT1313550B1 (it) 2002-09-09
TW200422057A (en) 2004-11-01
EP1354582A2 (en) 2003-10-22
PT1059913E (pt) 2005-01-31
EP1059913B1 (en) 2004-09-29
GB2350791A (en) 2000-12-13
HK1033277A1 (en) 2001-08-24
FR2853546A1 (fr) 2004-10-15
JP2002505271A (ja) 2002-02-19
HUP0101080A3 (en) 2001-12-28
NZ506644A (en) 2004-02-27
BE1012400A5 (fr) 2000-10-03
CO4930289A1 (es) 2000-06-27
AU749217B2 (en) 2002-06-20
SK13192000A3 (sk) 2001-02-12
GB0021495D0 (en) 2000-10-18
KR20010041657A (ko) 2001-05-25
MY129274A (en) 2007-03-30
HUP0101080A2 (hu) 2001-08-28
EP1059913A1 (en) 2000-12-20
FR2800277B1 (fr) 2004-06-25
TWI236912B (en) 2005-08-01
AR015729A1 (es) 2001-05-16
TWI248368B (en) 2006-02-01
BE1013648A5 (fr) 2002-05-07
NO331800B1 (no) 2012-04-02
CZ301967B6 (cs) 2010-08-18
FR2853546B1 (fr) 2006-04-07
DE69920668T2 (de) 2005-10-06
SK285139B6 (sk) 2006-07-07
CA2322845C (en) 2009-12-08
ES2228014T3 (es) 2005-04-01
FR2800277A1 (fr) 2001-05-04
TWI257870B (en) 2006-07-11
IL138248A (en) 2006-06-11
FR2775596B1 (fr) 2004-12-24
FR2881956A1 (fr) 2006-08-18
FR2775596A1 (fr) 1999-09-10
PE20000324A1 (es) 2000-04-13
IL138248A0 (en) 2001-10-31
CN1292684A (zh) 2001-04-25
NO20004299D0 (no) 2000-08-29
CZ20003222A3 (cs) 2000-12-13
ID25908A (id) 2000-11-09
JP2004189753A (ja) 2004-07-08
AU2836199A (en) 1999-09-20
GB2350791B (en) 2003-04-02
ITMI990452A1 (it) 2000-09-05
DE69920668D1 (de) 2004-11-04
NO20004299L (no) 2000-08-29
BR9908597A (pt) 2000-11-14
ATE277599T1 (de) 2004-10-15
CA2322845A1 (en) 1999-09-10
WO1999044584A1 (en) 1999-09-10
BE1013423A5 (fr) 2002-01-15

Similar Documents

Publication Publication Date Title
KR100443306B1 (ko) 사이클로스포린 또는 마크롤라이드를 포함하는 에멀젼예비농축물
KR100518135B1 (ko) 매크롤라이드를 안정화하는 방법
US20110152201A1 (en) Emulsion preconcentrates containing cyclosporin or a macrolide
US20100215734A1 (en) Pharmaceutical compositions
GB2380674A (en) Emulsion preconcentrates containing a cyclosporin or a macrolide
RU2181054C2 (ru) Микроэмульсионный предконцентрат
RU2235554C2 (ru) Предварительно приготовленные эмульсионные концентраты, содержащие циклоспорин или макролид
MXPA00008735A (en) Emulsion preconcentrates containing cyclosporin or a macrolide
HK1034038B (en) Emulsion preconcentrates containing cyclosporin or a macrolide
HK1103979A (en) Pharmaceutical compositions
PL184711B1 (pl) Prekoncentrat mikroemulsji

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20110617

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120728

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120728